{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T06:27:00Z","timestamp":1786688820027,"version":"build-2736575974"},"reference-count":95,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:p>Alzheimer\u2019s and Parkinson\u2019s disease are two CNS diseases with a large unmet need for disease-modifying therapies. Recently, two phase 3 clinical trials testing the GLP-1 analogue Semaglutide (Wegovy, Ozempic) in patients with Alzheimer\u2019s disease did not show improvements. This failure should not have been a surprise, since it has been known for many years that Semaglutide does not cross the blood-brain barrier (BBB) and enters the brain only in very small amounts. It is designed to stay in the blood stream and has a very long half-life in the blood (168 h). The GLP-1 analogue Liraglutide (Victoza), in contrast, has a much shorter half-life (13 h), and a phase 2 clinical trial showed improvements in cognitive tests after 1 year of treatment. GLP-1 receptor agonists have been tested in clinical trials in Parkinson\u2019s patients, and a similar picture emerged. Drugs that can cross the BBB well (exenatide, lixisenatide) show good protection, while a drug that cannot cross the BBB showed no effects (NLY01). Clearly, when treating CNS diseases, it is of importance to get the drug into the brain to ensure target engagement. This review will look at the clinical trials that have been conducted in more detail, describe the mode of action as derived from preclinical trials, and discuss novel strategies for getting GLP-1 receptor agonists into the brain to successfully treat CNS diseases.<\/jats:p>","DOI":"10.3389\/fnins.2026.1906426","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:32:05Z","timestamp":1786685525000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 and GIP class drugs have neuroprotective properties in Alzheimer\u2019s and Parkinson\u2019s disease"],"prefix":"10.3389","volume":"20","author":[{"given":"Christian","family":"H\u00f6lscher","sequence":"first","affiliation":[{"name":"Department of Neurology, Second Associated Hospital, Shanxi Medical University, Taiyuan","place":["Shanxi, China"]},{"name":"Kariya Pharmaceuticals Ltd.","place":["Copenhagen, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13195-024-01537-1","article-title":"Comparing regional brain uptake of incretin receptor agonists after intranasal delivery in CD-1 mice and the APP\/PS1 mouse model of Alzheimer\u2019s disease.","volume":"16","author":"Abdulhameed","year":"2024","journal-title":"Alzheimers Res. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.pneurobio.2016.10.001","article-title":"Insulin resistance and Parkinson\u2019s disease: A new target for disease modification?","author":"Athauda","year":"2016","journal-title":"Prog. Neurobiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.neuropharm.2017.09.023","article-title":"Protective effects of the GLP-1 mimetic exendin-4 in Parkinson\u2019s disease.","volume":"136","author":"Athauda","year":"2018","journal-title":"Neuropharmacology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jamaneurol.2018.4304","article-title":"Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients With Parkinson disease: A secondary analysis of the exenatide-PD trial.","volume":"76","author":"Athauda","year":"2019","journal-title":"JAMA Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3233\/JPD-181329","article-title":"What effects might exenatide have on non-motor symptoms in Parkinson\u2019s disease: A post hoc analysis.","volume":"8","author":"Athauda","year":"2018","journal-title":"J. Parkinsons Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson\u2019s disease: A randomised, double-blind, placebo-controlled trial.","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson\u2019s disease.","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J. Clin. Invest."},{"key":"B8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3233\/JPD-140364","article-title":"Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson\u2019s disease.","volume":"4","author":"Aviles-Olmos","year":"2014","journal-title":"J. Parkinsons Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP.","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/CE.S15525","article-title":"Lixisenatide: Evidence for its potential use in the treatment of type 2 diabetes.","volume":"6","author":"Barnett","year":"2011","journal-title":"Core Evid."},{"key":"B11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/path.5056","article-title":"The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer\u2019s disease.","volume":"245","author":"Batista","year":"2018","journal-title":"J. Pathol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.neuroscience.2014.02.022","article-title":"Lixisenatide rescues spatial memory and synaptic plasticity from amyloid \u03b2 protein-induced impairments in rats.","volume":"277","author":"Cai","year":"2014","journal-title":"Neuroscience"},{"key":"B13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.bbr.2016.10.033","article-title":"Lixisenatide attenuates the detrimental effects of amyloid \u03b2 protein on spatial working memory and hippocampal neurons in rats.","volume":"318","author":"Cai","year":"2017","journal-title":"Behav. Brain Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"fcaf103","DOI":"10.1093\/braincomms\/fcaf103","article-title":"LRRK2-associated parkinsonism with and without in vivo evidence of alpha-synuclein aggregates: Longitudinal clinical and biomarker characterization.","volume":"7","author":"Chahine","year":"2025","journal-title":"Brain Commun."},{"key":"B15","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.3390\/molecules27134315","article-title":"Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: A mini-review.","volume":"27","author":"Chavda","year":"2022","journal-title":"Molecules"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/ijo.2015.136","article-title":"Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes.","volume":"39","author":"Christensen","year":"2015","journal-title":"Int. J. Obes."},{"key":"B17","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.molmet.2015.07.008","article-title":"Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain.","volume":"4","author":"Cork","year":"2015","journal-title":"Mol. Metab."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/S0140-6736(26)00459-9","article-title":"Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer\u2019s disease (evoke and evoke+): Two phase 3, randomised, placebo-controlled trials.","volume":"407","author":"Cummings","year":"2026","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/s0166-2236(02)02181-1","article-title":"The placebo effect in Parkinson\u2019s disease.","volume":"25","author":"de la Fuente-Fern\u00e1ndez","year":"2002","journal-title":"Trends Neurosci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1007\/s40618-024-02320-7","article-title":"Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: A proof-of-concept clinical trial.","volume":"47","author":"Dei Cas","year":"2024","journal-title":"J. Endocrinol. Invest."},{"key":"B21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41591-025-04106-7","article-title":"Liraglutide in mild to moderate Alzheimer\u2019s disease: A phase 2b clinical trial.","volume":"32","author":"Edison","year":"2026","journal-title":"Nat. Med."},{"key":"B22","volume-title":"Evaluating KP405, a CNS -Penetrating GLP1\/GIP Analogue, in a Randomized, Placebo-Controlled Phase I Study in Healthy Elderly Participants and Parkinson\u2019s Disease Patients with Exploratory Analysis of Biomarkers in Brain-Derived Extracellular Vesicles.","author":"Eitan","year":"2026"},{"key":"B23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.neuropharm.2018.02.012","article-title":"Two novel dual GLP-1\/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson\u2019s disease.","volume":"133","author":"Feng","year":"2018","journal-title":"Neuropharmacology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nm.3761","article-title":"A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.","volume":"21","author":"Finan","year":"2015","journal-title":"Nat. Med."},{"key":"B25","article-title":"Exenatide as a disease modifying treatment for parkinson\u2019s disease- a randomised trial","volume-title":"Proceedings of the AD\/PD Conference","author":"Foltynie","year":"2025"},{"key":"B26","doi-asserted-by":"publisher","first-page":"102019","DOI":"10.1016\/j.molmet.2024.102019","article-title":"The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP\/PS1 mice.","volume":"89","author":"Forny Germano","year":"2024","journal-title":"Mol. Metab."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1016\/j.bcp.2008.03.011","article-title":"C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes.","volume":"75","author":"Gault","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fnagi.2016.00108","article-title":"In Alzheimer\u2019s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: Randomized, placebo-controlled, double-blind clinical trial.","volume":"8","author":"Gejl","year":"2016","journal-title":"Front. Aging Neurosci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1517\/13543784.15.8.887","article-title":"Investigational treatments for Type 2 diabetes mellitus: Exenatide and liraglutide.","volume":"15","author":"Gonz\u00e1lez","year":"2006","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B30","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.neurobiolaging.2012.04.009","article-title":"Liraglutide protects against amyloid-\u03b2 protein-induced impairment of spatial learning and memory in rats.","volume":"34","author":"Han","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"B31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jdiacomp.2013.12.009","article-title":"Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes.","volume":"28","author":"Henry","year":"2014","journal-title":"J. Diabetes Complications"},{"key":"B32","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1208\/s12248-008-9055-2","article-title":"CNS delivery via adsorptive transcytosis.","volume":"10","author":"Herv\u00e9","year":"2008","journal-title":"AAPS J."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.4212371","author":"Hogg","year":"2023","journal-title":"A Phase II, Randomized, Double-Blinded, Placebo-Controlled Trial of Liraglutide in Parkinson\u2019s Disease."},{"key":"B34","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1042\/BST20140016","article-title":"Insulin, incretins and other growth factors as potential novel treatments for Alzheimer\u2019s and Parkinson\u2019s diseases.","volume":"42","author":"H\u00f6lscher","year":"2014","journal-title":"Biochem. Soc. Trans."},{"key":"B35","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.neuropharm.2018.01.040","article-title":"Novel dual GLP-1\/GIP receptor agonists show neuroprotective effects in Alzheimer\u2019s and Parkinson\u2019s disease models.","volume":"136","author":"H\u00f6lscher","year":"2018","journal-title":"Neuropharmacology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"955258","DOI":"10.3389\/fnsyn.2022.955258","article-title":"Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer\u2019s and Parkinson\u2019s diseases.","volume":"14","author":"H\u00f6lscher","year":"2022","journal-title":"Front. Synaptic Neurosci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s40263-025-01226-z","article-title":"Incretin hormones GLP-1 and GIP normalize energy utilization and reduce inflammation in the brain in Alzheimer\u2019s disease and Parkinson\u2019s disease: From repurposed GLP-1 receptor agonists to novel dual GLP-1\/GIP receptor agonists as potential disease-modifying therapies.","volume":"39","author":"H\u00f6lscher","year":"2025","journal-title":"CNS Drugs"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1177\/13872877261458402","article-title":"Semaglutide showed limited improvements in patients with Alzheimer\u2019s disease: Revisiting the Evoke and Evoke+ clinical trials.","author":"H\u00f6lscher","year":"2026","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2202-13-33","article-title":"Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.","volume":"13","author":"Hunter","year":"2012","journal-title":"BMC Neurosci"},{"key":"B40","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ejphar.2010.10.008","article-title":"The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test.","volume":"650","author":"Isacson","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.neures.2006.04.008","article-title":"Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes.","volume":"55","author":"Iwai","year":"2006","journal-title":"Neurosci. Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.neuropharm.2018.01.013","article-title":"GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence.","volume":"136","author":"Jerlhag","year":"2018","journal-title":"Neuropharmacology"},{"key":"B43","volume-title":"Semaglutide Concentration in Cerebrospinal Fluid from Patients with Early Alzheimer\u2019s Disease After 12 Weeks of Subcutaneous Treatment.","author":"Johannsen","year":"2025"},{"key":"B44","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/1742-2094-9-276","article-title":"GLP-1 secretion by microglial cells and decreased CNS expression in obesity.","volume":"9","author":"Kappe","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"B45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1385\/JMN:18:1-2:07","article-title":"Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier.","volume":"18","author":"Kastin","year":"2002","journal-title":"J. Mol. Neurosci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/sj.ijo.0802206","article-title":"Entry of exendin-4 into brain is rapid but may be limited at high doses.","volume":"27","author":"Kastin","year":"2003","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"B47","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1677\/JOE-09-0132","article-title":"Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson\u2019s disease.","volume":"202","author":"Kim","year":"2009","journal-title":"J. Endocrinol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide.","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front. Endocrinol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"106550","DOI":"10.1016\/j.phrs.2022.106550","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment.","volume":"186","author":"Kopp","year":"2022","journal-title":"Pharmacol. Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.regpep.2004.08.026","article-title":"Glucagon-related peptide 1 (GLP-1): Hormone and neurotransmitter.","volume":"128","author":"Larsen","year":"2005","journal-title":"Regul. Pept."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.3233\/JAD-2010-1314","article-title":"GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer\u2019s disease.","volume":"19","author":"Li","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1073\/pnas.0806720106","article-title":"GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.","volume":"106","author":"Li","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1825379","DOI":"10.3389\/fendo.2026.1825379","article-title":"The novel GLP-1\/GIP dual receptor agonist DA5-CH is superior to tirzepatide and exendin-4 in the 6-OHDA Parkinson rat model.","volume":"17","author":"Lingyu","year":"2026","journal-title":"Front. Endocrinol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/bip.20998","article-title":"Polymeric micelles anchored with TAT for delivery of antibiotics across the blood-brain barrier.","volume":"90","author":"Liu","year":"2008","journal-title":"Biopolymers"},{"key":"B55","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","article-title":"Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson\u2019s disease.","volume":"303","author":"Liu","year":"2015","journal-title":"Neuroscience"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1002\/mds.22173","article-title":"Cut-off score of the Mattis dementia rating scale for screening dementia in Parkinson\u2019s disease.","volume":"23","author":"Llebaria","year":"2008","journal-title":"Mov. Disord."},{"key":"B57","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12017-012-8199-5","article-title":"The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-\u03b2 plaque and glial pathology in a mouse model of Alzheimer\u2019s disease.","volume":"15","author":"Long-Smith","year":"2013","journal-title":"Neuromol. Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e2231","DOI":"10.1002\/brb3.2231","article-title":"The GLP-1\/GIP dual-receptor agonist DA5-CH inhibits the NF-\u03baB inflammatory pathway in the MPTP mouse model of Parkinson\u2019s disease more effectively than the GLP-1 single-receptor agonist NLY01.","volume":"11","author":"Lv","year":"2021","journal-title":"Brain Behav."},{"key":"B59","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jad.2016.09.056","article-title":"Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study.","volume":"207","author":"Mansur","year":"","journal-title":"J. Affect. Disord."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.euroneuro.2017.08.433","article-title":"Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders.","volume":"27","author":"Mansur","year":"","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.3390\/ijms26115338","article-title":"GLP-1 analogues in the neurobiology of addiction: Translational insights and therapeutic perspectives.","volume":"26","author":"Marquez-Meneses","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1533317520953041","DOI":"10.1177\/1533317520953041","article-title":"The dual GLP-1\/GIP receptor agonist DA4-JC shows superior protective properties compared to the GLP-1 analogue liraglutide in the APP\/PS1 mouse model of Alzheimer\u2019s disease.","volume":"35","author":"Maskery","year":"2020","journal-title":"Am. J. Alzheimers Dis. Other Demen."},{"key":"B63","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/1533317511412046","article-title":"Mattis dementia rating scale 2: Screening for MCI and dementia.","volume":"26","author":"Matteau","year":"2011","journal-title":"Am. J. Alzheimers Dis. Other Demen."},{"key":"B64","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neuropharm.2013.08.005","article-title":"Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP\/PS1 mice, a model of Alzheimer\u2019s disease.","volume":"76","author":"McClean","year":"","journal-title":"Neuropharmacology"},{"key":"B65","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.neuropharm.2014.07.015","article-title":"Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer\u2019s disease.","volume":"86","author":"McClean","year":"","journal-title":"Neuropharmacology"},{"key":"B66","doi-asserted-by":"publisher","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","article-title":"The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease.","volume":"31","author":"McClean","year":"2011","journal-title":"J. Neurosci."},{"key":"B67","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","article-title":"Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson\u2019s disease: A randomised, double-blind, placebo-controlled trial.","volume":"23","author":"McGarry","year":"2024","journal-title":"Lancet Neurol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of lixisenatide in early Parkinson\u2019s disease.","volume":"390","author":"Meissner","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"102118","DOI":"10.1016\/j.molmet.2025.102118","article-title":"Glucose-dependent insulinotropic polypeptide (GIP).","volume":"95","author":"M\u00fcller","year":"2025","journal-title":"Mol. Metab."},{"key":"B70","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1).","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol. Metab."},{"key":"B71","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2174\/1567205016666190913155950","article-title":"A pilot study of exenatide actions in Alzheimer\u2019s disease.","volume":"16","author":"Mullins","year":"2019","journal-title":"Curr. Alzheimer Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1523\/JNEUROSCI.4920-04.2005","article-title":"Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation.","volume":"25","author":"Nyberg","year":"2005","journal-title":"J. Neurosci."},{"key":"B73","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/jnr.21349","article-title":"Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain.","volume":"85","author":"Nyberg","year":"2007","journal-title":"J. Neurosci. Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"11","DOI":"10.11648\/j.ajbio.20150301.13","article-title":"Age-related decrease in glucagon-like Peptide-1 in mouse prefrontal cortex but not in hippocampus despite the preservation of its receptor.","volume":"3","author":"Ohshima","year":"2015","journal-title":"Am. J. BioSci."},{"key":"B75","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s40478-021-01180-z","article-title":"Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer\u2019s disease.","volume":"9","author":"Park","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"key":"B76","doi-asserted-by":"publisher","first-page":"e58784","DOI":"10.1371\/journal.pone.0058784","article-title":"Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model.","volume":"8","author":"Parthsarathy","year":"2013","journal-title":"PLoS One"},{"key":"B77","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0165-6147(03)00160-3","article-title":"The glucagon-like peptides: A double-edged therapeutic sword?","volume":"24","author":"Perry","year":"2003","journal-title":"Trends Pharmacol. Sci."},{"key":"B78","doi-asserted-by":"publisher","first-page":"970925","DOI":"10.3389\/fnins.2022.970925","article-title":"The neuroprotective effects of glucagon-like peptide 1 in Alzheimer\u2019s and Parkinson\u2019s disease: An in-depth review.","volume":"16","author":"Reich","year":"2022","journal-title":"Front. Neurosci."},{"key":"B79","doi-asserted-by":"publisher","first-page":"2292461","DOI":"10.1080\/21688370.2023.2292461","article-title":"Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer\u2019s and Parkinson\u2019s diseases.","volume":"12","author":"Rhea","year":"2024","journal-title":"Tissue Barriers"},{"key":"B80","doi-asserted-by":"publisher","first-page":"e00712","DOI":"10.1016\/j.neurot.2025.e00712","article-title":"From metabolism to mind: The expanding role of the GLP-1 receptor in neurotherapeutics.","volume":"22","author":"Roy","year":"2025","journal-title":"Neurotherapeutics"},{"key":"B81","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nrn3381","article-title":"The brain reward circuitry in mood disorders.","volume":"14","author":"Russo","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"B82","doi-asserted-by":"publisher","first-page":"114187","DOI":"10.1016\/j.bcp.2020.114187","article-title":"Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer\u2019s and Parkinson\u2019s disease therapeutics.","volume":"180","author":"Salameh","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"R795","DOI":"10.1152\/ajpregu.00333.2015","article-title":"PPG neurons of the lower brain stem and their role in brain GLP-1 receptor activation.","volume":"309","author":"Trapp","year":"2015","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/dom.12506","article-title":"Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans.","volume":"17","author":"van Bloemendaal","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"B85","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","article-title":"Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: A phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.","volume":"405","author":"Vijiaratnam","year":"2025","journal-title":"Lancet"},{"key":"B86","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.pneurobio.2010.07.003","article-title":"Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: Role of peripherally secreted and centrally produced peptides.","volume":"92","author":"Vrang","year":"2010","journal-title":"Prog. Neurobiol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1177\/13872877251351329","article-title":"Associations of semaglutide with Alzheimer\u2019s disease-related dementias in patients with type 2 diabetes: A real-world target trial emulation study.","volume":"106","author":"Wang","year":"2025","journal-title":"J. Alzheimers Dis."},{"key":"B88","doi-asserted-by":"publisher","first-page":"8661","DOI":"10.1002\/alz.14313","article-title":"Associations of semaglutide with first-time diagnosis of Alzheimer\u2019s disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US.","volume":"20","author":"Wang","year":"2024","journal-title":"Alzheimers Dement."},{"key":"B89","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists.","volume":"31","author":"Xie","year":"2025","journal-title":"Nat. Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/14728222.2022.2079492","article-title":"Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson\u2019s disease.","volume":"26","author":"Yang","year":"2022","journal-title":"Expert Opin. Ther Targets"},{"key":"B91","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ejphar.2017.06.029","article-title":"A novel GLP-1\/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson\u2019s disease.","volume":"812","author":"Yuan","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","article-title":"Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson\u2019s disease.","volume":"24","author":"Yun","year":"2018","journal-title":"Nat. Med."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1428817","DOI":"10.1155\/2022\/1428817","article-title":"DA5-CH and semaglutide protect against neurodegeneration and reduce \u03b1-Synuclein levels in the 6-OHDA Parkinson\u2019s disease rat model.","volume":"2022","author":"Zhang","year":"2022","journal-title":"Parkinsons Dis."},{"key":"B94","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3233\/JPD-191768","article-title":"The novel dual GLP-1\/GIP receptor agonist DA-CH5 is superior to single GLP-1 receptor agonists in the MPTP model of Parkinson\u2019s disease.","volume":"10","author":"Zhang","year":"2020","journal-title":"J. Parkinsons Dis."},{"key":"B95","doi-asserted-by":"publisher","first-page":"170184","DOI":"10.1016\/j.peptides.2019.170184","article-title":"GIP has neuroprotective effects in Alzheimer and Parkinson\u2019s disease models.","volume":"125","author":"Zhang","year":"2020","journal-title":"Peptides"}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2026.1906426\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:32:07Z","timestamp":1786685527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2026.1906426\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":95,"alternative-id":["10.3389\/fnins.2026.1906426"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2026.1906426","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"article-number":"1906426"}}